Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Maternal-Fetal Medicine

Treatment Options During Pregnancy

At a Glance

The primary medical treatment for fetal CMV during pregnancy is high-dose valacyclovir (typically 8 grams per day). Starting this antiviral medication early can significantly lower the risk of passing the virus to your baby and reduce symptom severity if transmission has already occurred.

When a primary CMV infection is confirmed during pregnancy, the goal of treatment is twofold: to prevent the virus from passing to the fetus and to reduce the severity of symptoms if transmission has already occurred. Currently, medical management focuses on two main options, though their availability and effectiveness differ significantly.

High-Dose Valacyclovir

Valacyclovir is an antiviral medication that is commonly used to treat other herpesviruses. In the context of CMV and pregnancy, it is prescribed at a much higher dose than standard (typically 8 grams per day, often divided into four doses of 2 grams) [1][2].

  • Off-Label Use: It is important to know that prescribing high-dose valacyclovir for fetal CMV is considered an “off-label” use. When you pick it up, the pharmacy pamphlet will likely mention it is for genital herpes or shingles. Do not let this alarm you; off-label use is common in pregnancy when evidence supports its benefit. Because it is off-label, you may also encounter insurance hurdles requiring prior authorization by your doctor [3][4].
  • How it Works: Valacyclovir works by interfering with the virus’s ability to replicate itself. By lowering the “viral load” in the mother’s body, it aims to reduce the chance of the virus crossing the placenta [1][5].
  • Effectiveness: Clinical evidence suggests that starting high-dose valacyclovir shortly after a primary infection—especially in the first trimester—can significantly reduce the rate of vertical transmission [2][6]. It has also been shown to reduce the likelihood of a baby being born with severe symptoms [7][8].
  • Side Effects and Safety: While preventing kidney crystallization through extreme hydration is critical, the most common real-world side effects you may experience are nausea, headaches, and GI upset [9][10]. Taking 8 grams of medication a day is a significant undertaking, and being prepared for extreme nausea can help you manage it [5]. Your doctor may also monitor your kidney function through routine blood tests [9].

CMV Hyperimmune Globulin (HIG)

Hyperimmune Globulin (HIG) is a blood product made from the plasma of donors who have high levels of CMV antibodies. It is typically administered through an intravenous (IV) infusion [11].

  • Controversy and Evidence: While HIG was once widely used, recent large-scale, high-quality clinical trials have shown that it is not effective at preventing the virus from passing to the baby or reducing the risk of birth defects [11][12][3].
  • Current Status: Because of this lack of proven benefit, HIG is no longer considered the primary treatment for CMV in many medical centers, although it may still be discussed as an experimental or adjunctive option in specific cases [13][14].

Treatment Decision Tree

Deciding on a treatment path depends on the timing of your infection and your test results:

  1. Scenario: Primary Infection in First Trimester (Pre-Amniocentesis)
    • Goal: Prevention of transmission.
    • Action: Doctors often recommend starting high-dose valacyclovir immediately to lower the risk of the virus reaching the fetus [15][2].
  2. Scenario: Positive Amniocentesis (Fetal Infection Confirmed)
    • Goal: Reduction of symptoms.
    • Action: High-dose valacyclovir may be continued or started to improve outcomes for the baby [7][8].
  3. Scenario: Specialized or Rare Cases
    • Action: Consultation with a Maternal-Fetal Medicine (MFM) specialist and a Pediatric Infectious Disease expert is recommended to discuss individual risks and benefits [13][14].

Please note: Treatment with valacyclovir does not guarantee that the baby will not be infected, but it is currently the most evidence-supported medical intervention for reducing that risk [16][8].

Common questions in this guide

Am I a candidate for high-dose valacyclovir during my pregnancy?
Doctors typically recommend high-dose valacyclovir if you have a confirmed primary CMV infection during your first trimester or if an amniocentesis confirms fetal infection. Your maternal-fetal medicine specialist will determine if you are a candidate based on the timing of your infection.
What is the recommended dose of valacyclovir for fetal CMV?
The standard off-label dosage for treating fetal CMV is 8 grams per day, usually divided into four doses of 2 grams each. This is a significantly higher dose than what is typically used to treat other viral infections.
What are the side effects of high-dose valacyclovir during pregnancy?
The most common side effects are severe nausea, headaches, and gastrointestinal upset. You must also commit to drinking a very large amount of water every day to prevent kidney crystallization and help your body process the high dose of medication.
Should I consider hyperimmune globulin (HIG) for fetal CMV?
Recent high-quality clinical trials have shown that hyperimmune globulin is not effective at preventing CMV from passing to the baby or reducing birth defects. Because of this lack of proven benefit, most medical centers no longer consider HIG a primary treatment option.
What is the primary goal of fetal CMV treatment?
Treatment goals depend on when you are diagnosed. If you start treatment before an amniocentesis, the goal is to prevent the virus from passing to the baby. If an amniocentesis already confirms fetal infection, the goal shifts to reducing the severity of the baby's symptoms.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on when I was infected, am I a candidate for high-dose valacyclovir?
  2. 2.What is the recommended dose of valacyclovir for me, and how many times a day should I take it?
  3. 3.Do I need to have my kidney function (creatinine) tested before or during treatment?
  4. 4.Should we consider hyperimmune globulin (HIG), or does the evidence suggest valacyclovir is more effective?
  5. 5.If I start treatment, how will we monitor whether it is working for the baby?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Renal toxicity of high-dosage valacyclovir for secondary prevention of congenital cytomegalovirus infection: a dose regimen-related issue.

    Ville Y, Leruez-Ville M

    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2021; (58(4)):637-638 doi:10.1002/uog.24753.

    PMID: 34468055
  2. 2

    [Secondary Prevention of Fetal Cytomegalovirus Infection Through Valacyclovir Administration in Maternal Primary Infections During the Periconceptional Period and First Trimester of Pregnancy].

    Chatzakis C, Bourgon N, Leruez-Ville M, Ville Y

    Gynecologie, obstetrique, fertilite & senologie 2025; (53(7-8)):341-348 doi:10.1016/j.gofs.2025.03.010.

    PMID: 40185476
  3. 3

    Describing the Impact of Maternal Hyperimmune Globulin and Valacyclovir on the Outcomes of Cytomegalovirus Infection in Pregnancy: A Systematic Review.

    Fitzpatrick A, Cooper C, Vasilunas N, Ritchie B

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022; (75(8)):1467-1480 doi:10.1093/cid/ciac297.

    PMID: 35438780
  4. 4

    Management of cytomegalovirus infection in pregnancy: is it time for valacyclovir?

    Zammarchi L, Lazzarotto T, Andreoni M, et al.

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020; (26(9)):1151-1154 doi:10.1016/j.cmi.2020.04.006.

    PMID: 32289479
  5. 5

    The effect of valacyclovir on secondary prevention of congenital cytomegalovirus infection, following primary maternal infection acquired periconceptionally or in the first trimester of pregnancy. An individual patient data meta-analysis.

    Chatzakis C, Shahar-Nissan K, Faure-Bardon V, et al.

    American journal of obstetrics and gynecology 2024; (230(2)):109-117.e2 doi:10.1016/j.ajog.2023.07.022.

    PMID: 37473793
  6. 6

    The effect of valacyclovir on secondary prevention of congenital cytomegalovirus infection.

    Chatzakis C, Bourgon N, Fourgeaud J, et al.

    Best practice & research. Clinical obstetrics & gynaecology 2025; (103()):102679 doi:10.1016/j.bpobgyn.2025.102679.

    PMID: 41175678
  7. 7

    Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial.

    Shahar-Nissan K, Pardo J, Peled O, et al.

    Lancet (London, England) 2020; (396(10253)):779-785 doi:10.1016/S0140-6736(20)31868-7.

    PMID: 32919517
  8. 8

    Treatment with valacyclovir during pregnancy for prevention of congenital cytomegalovirus infection: a real-life multicenter Italian observational study.

    Zammarchi L, Tomasoni LR, Liuzzi G, et al.

    American journal of obstetrics & gynecology MFM 2023; (5(10)):101101 doi:10.1016/j.ajogmf.2023.101101.

    PMID: 37516151
  9. 9

    Risk factors related to postpartum hepatic inflammation in pregnant women with chronic hepatitis B.

    Li L, Zou H, Xu M, et al.

    The Journal of international medical research 2020; (48(11)):300060520966439 doi:10.1177/0300060520966439.

    PMID: 33208011
  10. 10

    Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B.

    Lee YS, Bang SM, Lee YS

    Journal of clinical medicine 2021; (10(11)) doi:10.3390/jcm10112320.

    PMID: 34073357
  11. 11

    A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection.

    Hughes BL, Clifton RG, Rouse DJ, et al.

    The New England journal of medicine 2021; (385(5)):436-444 doi:10.1056/NEJMoa1913569.

    PMID: 34320288
  12. 12

    New evidence on prognostic features, prevention and treatment of congenital Cytomegalovirus infection.

    Sebghati M, Khalil A

    Current opinion in obstetrics & gynecology 2020; (32(5)):342-350 doi:10.1097/GCO.0000000000000651.

    PMID: 32739974
  13. 13

    Cytomegalovirus Infection in Pregnancy Prevention and Treatment Options: A Systematic Review and Meta-Analysis.

    Rybak-Krzyszkowska M, Górecka J, Huras H, et al.

    Viruses 2023; (15(11)) doi:10.3390/v15112142.

    PMID: 38005820
  14. 14

    Provider-Led Interventions to Reduce Congenital Cytomegalovirus.

    Trisko E, Gosnell K, Douglas T, Wu K

    Journal of midwifery & women's health 2025; (70(4)):576-592 doi:10.1111/jmwh.13749.

    PMID: 40152197
  15. 15

    Impact of early treatment with valaciclovir on vertical cytomegalovirus transmission.

    Journal of paediatrics and child health 2023; (59(8)):1009 doi:10.1111/jpc.16464.

    PMID: 37434558
  16. 16

    Antenatal Imaging and Neonatal Outcome in Infants with Congenital Cytomegalovirus Infection: The Effect of Valaciclovir.

    Arcieri F, Vasta A, Sorrenti S, et al.

    Journal of clinical medicine 2026; (15(2)) doi:10.3390/jcm15020809.

    PMID: 41598745

This page provides information about fetal CMV treatment options during pregnancy for educational purposes only. Always consult your Maternal-Fetal Medicine specialist or Obstetrician to determine the safest and most effective treatment plan for your specific pregnancy.

Get notified when new evidence is published on Fetal cytomegalovirus syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.